Introduction: Managing elderly patients with type 2 diabetes mellitus (T2DM) is complex due to comorbidities, hypoglycemia risk, polypharmacy, renal issues, and costs. This survey evaluated Indian healthcare professionals’ (HCPs) perceptions regarding the clinical usefulness of the glipizide + metformin fixed-dose combination (FDC) for elderly patients with T2DM. Methods: This cross-sectional, questionnaire-based survey was conducted to evaluate the knowledge, attitudes, and practices (KAP) of Indian HCPs supplemented by expert insights from focus group discussions (FGDs) concerning the clinical utility of this FDC for elderly patients with T2DM. Data were collected using a structured, self-administered questionnaire developed from a comprehensive literature review on the efficacy, safety, clinical utility, and prescribing patterns of the FDC. Results: Of the 833 HCPs, 585 (70.22%) identified hypoglycemia as the main challenge in managing elderly T2DM patients. Cost and accessibility of medications were concerns for 449 (53.90%) HCPs, while 446 (53.54%) noted that renal impairment affected the drug metabolism. Key priorities for oral hypoglycemic agents included reducing the risk of hypoglycemia by 579 (69.51%) HCPs, perceived cost-related considerations by 527 (63.27%), and minimizing renal clearance by 447 (53.66%). A total of 571 (68.55%) HCPs preferred glipizide for its short half-life and renal safety. Approximately 419 (50.30%) HCPs supported this FDC use in mild-to-moderate renal impairment with dose adjustment. Conclusion: Healthcare professionals in India perceived this FDC as a cost-effective choice for elderly T2DM patients, citing lower hypoglycemia risk, renal safety, and reduced pill burden. Highlight its clinical value and benefit for personalised T2DM management in the elderly.
No takes yet. Share an insight, caveat, or question.
Unnikrishnan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: